This research blend combines a NAD + -associated coenzyme component , a mitochondria-derived peptide , and an NNMT-pathway small-molecule analog into a single laboratory formulation for investigational use
However, compounds with an amino acid-based structure (i.e., peptides, proteins, peptidomimetics), including those used in therapeutic applications, have a number of serious limitations, such as conformational instability, short duration of action (short half-life), and insufficient penetration through the bloodbrain barrier (BBB) [3,4,5]
When studied together as a blend, it is theorized that their complementary mechanisms may enhance healing processes beyond what either peptide demonstrates alone
Draw 5mL of non-bacteriostatic SWFI into the 5mL syringe (or in parts)